Amarin Corporation Plc -adr trades in the stock market as ticker AMRN. Business Summary & Profile For Amarin Corporation Plc -adr.

Amarin Corporation Plc -adr

Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. Its lead product candidate includes AMR101, a prescription grade omega-3 fatty acid, which is in second Phase III clinical trial for the treatment of high triglyceride levels in statin-treated patients who have mixed dyslipidemia. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.
www.amarincorp.com
16 Employees
Last Reported Date: 03/16/11
Founded in 1989
LAST $8.90 USD
CHANGE TODAY -0.445 -4.76%
VOLUME 1.3M
As of 12:07 PM 02/17/12 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of AMARIN CORPORATION PLC -ADR (AMRN)

OPEN
$9.35
PREVIOUS CLOSE
$9.35
DAY HIGH
$9.38
DAY LOW
$8.88
52 WEEK HIGH
05/27/11 - $19.87
52 WEEK LOW
12/15/11 - $5.99
MARKET CAP
1.2B
AVERAGE VOLUME 10 D
2.3M
EPS TTM
$-2.49
SHARES OUTSTANDING
135.8M
AMRN Does Not Pay Dividends
P/E TTM
--
K = Thousands  M = Millions  B = Billions

related news for AMARIN CORPORATION PLC -ADR (AMRN)

Amarin stock rises on news of FDA move [The Day, New London, Conn.]

Key developments for AMARIN CORPORATION PLC -ADR (AMRN)

Amarin Corporation plc Appoints Steven Ketchum as President of Research and Development and Senior Vice President, Effective February 16, 2012

Amarin Corporation plc announced that Steven Ketchum, Ph.D., has been appointed President of Research and Development, Senior Vice President, effective February 16, 2012. Dr. Ketchum will be responsible for Amarin's drug discovery, preclinical and clinical development program and regulatory and medical affairs activities, including the ongoing development and regulatory review support for Amarin's lead product candidate, AMR101. Most recently, Dr. Ketchum served as Senior Vice President, Research and Development for Sunesis Pharmaceuticals. Prior to Sunesis, Dr. Ketchum was Senior Vice President, Research and Development and Medical Affairs at Reliant Pharmaceuticals.

Amarin Corporation plc is Tapping Proceeds from a Maximum $172.5 Million Debt Offering

Amarin Corporation plc is tapping proceeds from a maximum $172.5 million debt offering by one of its subsidiaries to finance commercialisation of its new treatment against blood compounds harmful to the heart. The Dublin company has estimated that the US market potential for its heart disease drug is in excess of $1 billion a year, with 100 million people worldwide meeting the requirements for treatment by the drug. Amarin announced that Corsicanto Ltd., priced its offering of $150 million in exchangeable senior notes due 2032. The transaction is due to close next Monday.

Amarin To Seek Acquisitions

Amarin Corporation plc is considering partnership, acquisition and self-commercialization for marketing and sale of AMR101.

AMRN Competitors

Company Last Change
No competitor information is available for AMRN.
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation AMRN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

AMRN

 | 

AMRN transactions

Type
Date
Target
No transactions in the last 6 months.
Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed
[at noodls] - BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics ...
  Read More...
Amarin Announces Leadership Changes
[at noodls] - BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics ...
  Read More...
Amarin Reports Third Quarter 2013 Financial Results and Provides Update on Operations
[at noodls] - BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics ...
  Read More...
Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
[at noodls] - BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics ...
  Read More...
U.S. FDA panel votes against expanded use of Amarin drug
[Reuters - UK Focus] - Amarin Corporation Plc's triglyceride-lowering drug Vascepa should not be approved for use in a broader patient population until results from an additional study have been analyzed, an advisory panel to ...
  Read More...
Amarin Announces 30th Patent for Vascepa(R)
[at noodls] - BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve ...
  Read More...
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations
[at noodls] - Conference Call Set for 4:30 p.m. EDT Today BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/07/14 -- Amarin Corporation plc (NASDAQ: AMRN) , a biopharmaceutical company focused on the commercialization ...
  Read More...
4:02 pm Amarin beats by $0.01, misses on revs
  Read More...
Amarin to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
[at noodls] - Category: Baystreet Newswire Company: Issuer Direct ID: 418836 Date: Thursday, August 07, 2014 Ticker: NASDAQ:AMRN BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 7, 2014 / Amarin Corporation ...
  Read More...
Amarin to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
[at noodls] - Category: Baystreet Newswire Company: Issuer Direct ID: 418836 Date: Thursday, August 07, 2014 Ticker: NASDAQ:AMRN BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 7, 2014 / Amarin Corporation ...
  Read More...

Write Comment Create Account
Subject Author
Vascepa- Recognition gaining momentum
As evidenced by the positive mention in a medical segment on the meta-analysis "fish oil&am...
kaylawa
Buyout or Partnership only AH?
Assuming AMRN decides to either partner up or take a buyout when would this probably be announced. ...
tung1953
Anyone buying 20$ strike calls?
I am mostly maxed out on purchasing shares, but like how cheap the 20$ calls are for dec, jan. anyon...
mrkincai
Just posting
Hey all of you Amarin folks how goes that $15pps or better yet the $25 buyout? Like I said before I...
y0da7119
yOda
If .81 cents higher this stock goes, YODA can post here no more! LMAO...
rtellis444
Can anyone confirm that Amarin's under a quiet period?
Anyone call IR?...
williams4076
My neighbor is NOT buying ANYTHING from a muslim owned business
Sort of makes sense since they are threatening &quot;1.5 B osamas&quot; out there.<br /&g...
ridergirlatheart
Patent and Generic Drug Product Data Last Updated: September 17, 2012 and After Hours Trade
Patent and Generic Drug Product Data Last Updated: September 17, 2012 <br /> Patent Expires 20...
alliedgm
AMRN in the orange book patent until 2020
Wont let me post the link but it is on twitter <br /> Why is no one talking about this?...
tabanfar27
More Than Just Fish Oil
From ThatWasIt linked BASF patent info:<br /> <br /> United States Patent 8,258,371 <...
rugers6
dropping today
This will close today beteeen 13.36 and 13.45 or very close to...
y0da7119
Vacsepa made it last night special update in orange book
Great news guys...
mousemouse595
Patent data now updated in fda orange book
Wow nce looks positive now...
mousemouse595
Orange book updated with vascepa last night open price giess?
Wow surprise news....
mousemouse595
Shorties burn on hell
Time....
mousemouse595
Management burn the shorties
Chume....
mousemouse595
Trading Halted - Or Not
Usually there is some pre-market activity but I don&#39;t see any today. Probably just a slow s...
maxcoatinc
Orange book current through July
Stop saying it is updated. <br /> <br /> Accessdata.fda.gov/scripts/cder/ob/default.cfm&...
mousemouse595
Bring Home the Bacon with Amarin Corporatio ..
A new high was reached with Amarin Corporatio today with a percentage change at -26.63%. We may be s...
wilderlindsey798@ymail.com
Anybody using covered calls or options?
I did margin some shares(not full margin) a little while ago and sold the Jan 15 Calls at $3. My co...
ktsven
New Longs
Welcome --- some of us have been here for years but I for one always welcome fresh points of view.&l...
akanz2
Serious BO question from newbie
A little over 2 years ago I came into some money, and at a friends suggestion, invested it all in AM...
A Yahoo! User
Have you seen this OB update?
Have you seen that?<br /> It&#39;s just popped up! It appears $AMRN Vascepa is in Orange B...
slamdunk1981
Guess buyout without nce 25 with nce 40
Ceo #$%$ is sleeping...
mousemouse595
@ Choubix and Swalchie
Choubix -thanks for those kind words earlier but Jesse and Kayla ( as well as some others ) are the...
akanz2
The information contained herein does not suggest or imply and should not be construed, in any manner, a guarantee of future performance and/or investment advice.www.nasdaqstockranking.com is not a registered financial advisor or otherwise qualified as investment professional. The content posted here are only the opinion of the poster and should not be taken as recommendations to buy or sell any security or financial instrument. Trading and investing inherently involves the risk of significant loss of money, and can involve the risk of loss of more than the amount invested. Before executing any trade readers are strongly cautioned to consult with a financial adviser of their choosing. www.nasdaqstockranking.com, its affiliates and partners, shall have no liability for investment or other decisions based upon any Content and/or decisions based upon our syndicated page content.
@2012 www.nasdaqstockranking.com - info {at} www.nasdaqstockranking.comContactUs